Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Financial Resilience | Bausch Health's Q3 2024 results showcase robust growth, with revenues of $2.51 billion marking a 12% year-over-year increase and 9% organic growth |
Debt Dilemma | Explore the complexities of Bausch Health's $21.5 billion debt burden and its impact on strategic initiatives, including potential bankruptcy concerns |
Strategic Crossroads | Delve into Bausch Health's plans for asset separation, particularly the Bausch+Lomb division, and how debt issues may affect these crucial moves |
Market Sentiment | Analysts offer mixed views, with price targets ranging from $8 to $11, reflecting the tension between strong performance and financial challenges |
Metrics to compare | BHC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBHCPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.4x | 19.1x | −0.5x | |
PEG Ratio | 0.03 | 0.11 | 0.00 | |
Price/Book | −3.8x | 1.4x | 2.6x | |
Price / LTM Sales | 0.2x | 2.1x | 3.2x | |
Upside (Analyst Target) | 43.9% | 71.4% | 47.4% | |
Fair Value Upside | Unlock | 31.6% | 7.7% | Unlock |